The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial led by UCL scientists. It successfully lowered the level of the harmful huntingtin protein in the nervous system.
After over a decade in pre-clinical development, this first human trial of huntingtin-lowering drug began in late 2015, led by Professor Sarah Tabrizi (UCL Institute of Neurology) and sponsored by Ionis Pharmaceuticals.
The trial involved enrolling 46 patients with early Huntington’s disease at nine study centres in the UK, Germany and Canada.
Each patient received four doses of either IONIS-HTTRx or placebo, given by injection into the spinal fluid to enable it to reach the brain. As the phase 1/2a trial progressed, the dose of IONIS-HTTRx was increased several times according to the ascending-dose trial design.
Patient safety was monitored throughout the study by an independent safety committee.
Today’s announcement at completion of the trial confirms that IONIS-HTTRx was well-tolerated by the trial participants and its safety profile supports further testing in patients.
Professor Tabrizi, Director of the UCL Huntington’s Disease Centre and IONIS-HTTRx Global Chief Investigator, said: “The results of this trial are of ground-breaking importance for Huntington’s disease patients and families. For the first time a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well-tolerated. The key now is to move quickly to a larger trial to test whether the drug slows disease progression.”
A major unknown was whether the trial would show that IONIS-HTTRx could lower the level of mutant huntingtin protein in the nervous system. Using an ultra-sensitive assay, concentrations of the protein were measured in each patient’s spinal fluid before and after treatment.
As hoped, IONIS-HTTRx produced significant, dose-dependent lowering of the level of mutant huntingtin – the first time the protein known to cause Huntington’s has been lowered in the nervous system of patients.
As a result of these successful outcomes, Ionis’ partner, Roche, has exercised its option to license IONIS-HTTRx and assumes responsibility for further development, regulatory activities and commercialization activities. Meanwhile, Ionis announced in June that all patients in the completed trial would be offered a place in an open-label extension to receive IONIS-HTTRx.
Learn more: Drug lowers deadly Huntington’s disease protein
The Latest on: Huntington’s disease
- Parkinson's disease breakthrough seen in mouse modelon June 25, 2020 at 6:37 pm
Researchers from the University of California San Diego School of Medicine have found a way to create new neurons in a mouse model of Parkinson's disease. The severely debilitating and progressive ...
- Family of former FOX 2 reporter Kathy Walsh plan global yoga Zoom-athon to fight Huntington's Diseaseon June 25, 2020 at 6:17 pm
The disease affects the brain and body movement - but Kathy still does yoga and her family hopes you will do it too. You can raise money to help fight this disease and you don't even have to leave ...
- Family of Kathy Walsh plan global yoga Zoom-athon to fight Huntington's Diseaseon June 25, 2020 at 4:51 pm
They are rolling out 10 classes Saturday, June 27 for all ages and abilities for people across the globe to take a class for $15 or get an all day pass for $25.
- One-time treatment generates new neurons, eliminates Parkinson's disease in miceon June 25, 2020 at 12:20 pm
Researchers have discovered that a single treatment to inhibit a gene called PTB in mice converts native astrocytes, brain support cells, into neurons that produce the neurotransmitter dopamine. As a ...
- Myasthenia Gravis Disease Treatment Market Size 2020 by Manufacturers, Type, Application, Regions and Market Growth to 2026on June 25, 2020 at 4:22 am
Final Report will add the analysis of the impact of COVID-19 on this industry." “Myasthenia Gravis Disease Treatment Market” report 2020 delivers future development strategies, key companies, ...
- Winston-Salem woman raises awareness about Huntington’s diseaseon June 24, 2020 at 5:23 pm
A local woman is advocating for compassion and awareness of a neurodegenerative disease that runs in her family. At 34 years old Lauren Holder makes all of her father ...
- Yoga in Your Park raises funds for Huntington's Diseaseon June 24, 2020 at 2:46 am
MICHIGAN — It's being called an all-day global yoga session, focused on finding a cure for Huntington's Disease. Yoga has shown to be very therapeutic for those with Huntington's Disease, even ...
- Yasaman Gholamalipour awarded fellowship by Huntington’s Disease Society of Americaon June 23, 2020 at 7:09 am
UMass Medical School postdoctoral associate Yasaman Gholamalipour, PhD, was awarded the Huntington’s Disease Society of America Berman-Topper Family HD Career Development Fellowship for 2020.
- How COVID-19 is changing the way doctors care for patients with Huntington’s disease | Expert Opinionon June 23, 2020 at 4:06 am
While there’s no substitute for personal contact, we were amazed to discover that telemedicine allowed our Huntington's patients to teach us skills we wouldn’t have learned had we met them in the ...
- Treatment underway in study of uniQure gene therapy in Huntington's diseaseon June 19, 2020 at 4:49 am
The first two participants have been treated in a 26-subject Phase 1/2 clinical trial evaluating uniQure's (NASDAQ:QURE) AMT-130 in patients with Huntington's disease (HD), an inherited neurod ...
via Google News and Bing News